April 23, 2026
The US Department of Justice has reclassified certain cannabis products from Schedule I to Schedule III controlled substances, representing a significant policy shift in how the federal government categorizes marijuana. Acting Attorney General Todd Blanche made the change for FDA-covered cannabis products and those with state medical licenses, placing them in the same category as prescription medications like codeine-containing Tylenol rather than heroin. The reclassification, directed by President Trump, aims to facilitate increased medical research and patient access to cannabis treatments, though marijuana remains federally illegal.
Who is affected
What action is being taken
Why it matters
What's next
Read full article from source: BBC